Responsibility in Drug Advertising Act of 2025

119th Congress Introduced by Rosa DeLauro

The Responsibility in Drug Advertising Act of 2025 mandates clear drug ads, ensuring consumers access accurate info on medications, enhancing safety and informed choices.

Introduced in House

# Summary of HR 1117: Responsibility in Drug Advertising Act of 2025 ## Bill Overview **Bill Number:** HR 1117 **Title:** Responsibility in Drug Advertising Act of 2025 **Status:** Introduced in House **Introduced Date:** April 10, 2025 **Primary Sponsor:** Representative Rosa L. DeLauro **Related Bills:** S 483 (companion bill) ## Purpose and Intent The **Responsibility in Drug Advertising Act of 2025** aims to enhance the accountability and transparency of pharmaceutical advertising. The bill seeks to ensure that drug advertisements provide clear, accurate, and comprehensive information to consumers, thereby promoting informed decision-making regarding medication use. ## Key Provisions While the specific text of HR 1117 is not provided, the following provisions are typically included in similar legislation: - **Disclosure Requirements:** Pharmaceutical companies would be mandated to disclose potential side effects, contraindications, and the effectiveness of drugs in a clear and understandable manner. - **Advertising Standards:** Establishment of stricter guidelines for the content and presentation of drug advertisements to prevent misleading claims. - **Penalties for Non-Compliance:** Introduction of penalties for companies that fail to adhere to the new advertising standards, including fines and potential restrictions on advertising. - **Consumer Education Initiatives:** Funding for programs aimed at educating consumers about prescription medications and their risks and benefits. ## Impact The bill is expected to affect: - **Pharmaceutical Companies:** Increased compliance costs due to new advertising regulations and potential penalties for non-compliance. - **Healthcare Providers:** Enhanced information available to share with patients, leading to better-informed discussions about medication options. - **Consumers:** Greater access to accurate information about medications, which may lead to improved health outcomes and reduced adverse effects from medications. ## Legislative Timeline - **April 10, 2025:** HR 1117 was filed and read for the first time, with rules suspended for a second reading and referral to the Committee on House Management. - **April 14, 2025:** The bill was returned by the committee with a "Do Pass" recommendation. - **May 5, 2025:** The bill died in the House at Sine Die adjournment, indicating it did not progress to a vote or further consideration. ## Conclusion The **Responsibility in Drug Advertising Act of 2025** represents an effort to reform how pharmaceutical products are marketed to consumers, aiming to foster a more informed public and enhance the safety of medication use. Although the bill did not advance, its introduction highlights ongoing discussions about drug advertising practices and consumer protection in healthcare.